Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 280

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Open access
Zinzani, Pier Luigi, Musuraca, Gerardo, Tani, Monica, Stefoni, Vittorio, Marchi, Enrica, Fina, Mariapaola, Pellegrini, Cinzia, Alinari, Lapo, Derenzini, Enrico, de Vivo, Antonio, Sabattini, Elena, Pileri, Stefano, Baccarani, Michele·2007·Journal of Clinical Oncology

Abstract

Purpose: To determine the antitumor activity of the proteasome inhibitor bortezomib in patients with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma unspecified (PTCLU) with isolated skin involvement. Patients and Methods: From May 2005 to June 2006 at our institute, we treated patients with previously pretreated CTCL or PTCLU using bortezomib as a single agent, at a dose of 1.3 mg/m 2 intravenously on days 1, 4, 8, and 11, every 21 days for a total of six cycles. Results: Fifteen patients were registered, of whom 12 (10 CTCL, all mycosis fungoides, and two PTCLU with isolated skin involvement) were assessable. The overall response rate was 67%, with two (17%) complete remissions and six (50%) partial remissions. The remaining four patients had disease progression. Histologically, the responder patients were seven with CTCL and one with PTCLU with isolated skin involvement. All responses were durable, lasting from 7 to 14 or more months. Overall, the drug was well tolerated, with no grade 4 toxicity. The most common grade 3 toxicities were neutropenia (n = 2), thrombocytopenia (n = 2), and sensory neuropathy (n = 2). Conclusion: This study suggests that bortezomib was well tolerated and has significant single-agent activity in patients with cutaneous T-cell lymphoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2007.11.4207

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 280

Metadata

Authors
Zinzani, P. L., Musuraca, G., Tani, M., Stefoni, V., Marchi, E., Fina, M., Pellegrini, C., Alinari, L., Derenzini, E., de Vivo, A., Sabattini, E., Pileri, S., & Baccarani, M.
Venue
Journal of Clinical Oncology
Published
2007-09-20
Volume
25
Issue
27
Pages
4293-4297
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2057290270
Cited by
280
References
21
FWCI
18.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2007.11.4207
The paper
Zinzani, P. L., Musuraca, G., Tani, M., Stefoni, V., Marchi, E., Fina, M., Pellegrini, C., Alinari, L., Derenzini, E., de Vivo, A., Sabattini, E., Pileri, S., & Baccarani, M. (2007). Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.11.4207

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.